Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Earning its stripes

24.03.2011
Zebrafish model of human melanoma reveals new cancer gene

Looking at the dark stripes on the tiny zebrafish you might not expect that they hold a potentially important clue for discovering a treatment for the deadly skin disease melanoma.

Yet melanocytes, the same cells that are are responsible for the pigmentation of zebrafish stripes and for human skin color, are also where melanoma originates. Craig Ceol, PhD, assistant professor of molecular medicine at the University of Massachusetts Medical School, and collaborators at several institutions, used zebrafish to identify a new gene responsible for promoting melanoma. In a paper featured on the cover of the March 24 issue of Nature, Dr. Ceol and colleagues describe the melanoma-promoting gene SETDB1.

"We've known for some time that there are a number of genes that are responsible for the promotion and growth of melanoma," said Ceol, who completed the research while a postdoctoral fellow in the lab of Howard Hughes Medical Institute investigator Leonard Zon, MD, at Children's Hospital Boston. "With existing methods, it had been difficult to identify what those genes are. By developing the new approach described in this paper, we were able to isolate SETDB1 as one of those genes."

Cases of melanoma, an aggressive form of skin cancer, have been on the rise in the United States: in 2009 alone, 68,000 new cases were diagnosed and 8,700 people died of the disease. Though it accounts for less than 5 percent of all skin cancers, it is responsible for the majority of deaths from skin cancers and has a poor prognosis when diagnosed in its advanced stages. Early signs of melanoma include changes to the shape or color of existing moles or the appearance of a new lump anywhere on the skin.

Approximately 60 percent of human melanoma cases are caused by a mutation in the BRAF gene that drives proliferation of melanocytes, the cells responsible for skin pigmentation. Because the BRAF mutation is also found in benign moles, scientists hypothesized that the single mutation alone wasn't sufficient enough to cause melanoma. Ceol and colleagues set out to locate other genes implicated in this disease by focusing on areas of the genome that were overrepresented in melanoma cells, hypothesizing that there were genes in these regions that enabled cells to grow unchecked, leading to cancerous tumors. To evaluate genes from an overrepresented region of chromosome 1, Ceol created a technique called MiniCoopR to deliver the test genes, one-by-one, to transgenic zebrafish models with the melanoma-causing BRAF mutation. These fish also lacked the tumor suppressing gene p53.

"The MiniCoopR technique allows us to build melanocytes with whatever genes we want," said Ceol. "With it, we can test individual genes by placing them in the melanocytes and observing how those genes affect melanoma growth."

Painstakingly analyzing more than 2,100 tumors from more than 3,000 zebrafish, researchers found that in fish with the SETDB1 gene, melanoma not only appeared earlier, but grew faster and invaded more deeply into the neighboring muscle and spinal tissue. With this new information, researchers screened 100 human melanomas for the SETDB1 gene. In 70 percent of the sample tumors, SETDB1 was present at high levels, indicating that SETDB1 may be involved in the formation of a majority of human melanomas."

Further analysis showed that SETDB1 produces an enzyme that turns other genes on or off and is overrepresented in other forms of cancer, such as ovarian, breast and liver cancer. "It's clear that SETDB1 is up-regulated and that it's altering the activity levels of other genes," said Ceol. "Because SETDB1 regulates several genes, we still don't know which of its targets promote melanoma."

An abnormally high level of the SETDB1 enzyme may provide clinicians a means of identifying melanoma before patients experience symptoms. It may also provide an enticing target for pharmaceutical intervention. "Enzymes like SETDB1 are particularly attractive as drug targets because they are so amenable to inhibition by small molecules, which could potentially block the cancer causing activity," said Ceol.

About the University of Massachusetts Medical School

The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $255 million in research funding annually, 80 percent of which comes from federal funding sources. The work of UMMS researcher Craig Mello, PhD, an investigator of the prestigious Howard Hughes Medical Institute (HHMI), and his colleague Andrew Fire, PhD, then of the Carnegie Institution of Washington, toward the discovery of RNA interference was awarded the 2006 Nobel Prize in Medicine and has spawned a new and promising field of research, the global impact of which may prove astounding. UMMS is the academic partner of UMass Memorial Health Care, the largest health care provider in Central Massachusetts.

Jim Fessenden | EurekAlert!
Further information:
http://www.umassmed.edu

Further reports about: BRAF Earning Medical Wellness MiniCoopR Nobel Prize SETDB1 cancerous tumor skin cancer

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>